rs36210737
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The ENST00000003084.11(CFTR):c.3302T>A(p.Met1101Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000372 in 1,613,458 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. M1101R) has been classified as Pathogenic.
Frequency
Consequence
ENST00000003084.11 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.3302T>A | p.Met1101Lys | missense_variant | 20/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.3302T>A | p.Met1101Lys | missense_variant | 20/27 | 1 | NM_000492.4 | ENSP00000003084 | P2 | |
ENST00000456270.1 | n.177+4486A>T | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 151998Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251100Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135706
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1461460Hom.: 0 Cov.: 31 AF XY: 0.00000275 AC XY: 2AN XY: 727016
GnomAD4 genome AF: 0.0000197 AC: 3AN: 151998Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 74214
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:8
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 13, 2022 | The p.M1101K pathogenic mutation (also known as c.3302T>A), located in coding exon 20 of the CFTR gene, results from a T to A substitution at nucleotide position 3302. The methionine at codon 1101 is replaced by lysine, an amino acid with similar properties. In one study, this mutation was identified in three homozygous individuals with elevated sweat chloride levels; two of these individuals were pancreatic insufficient (Stanke F et al. J. Med. Genet., 2008 Jan;45:47-54). This mutation is associated with decreased lung function, elevated sweat chloride levels, and pancreatic insufficiency (Sosnay PR et al. Nat. Genet., 2013 Oct;45:1160-7). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Apr 22, 2020 | Disease-causing CFTR variant. See www.CFTR2.org for phenotype information. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 05, 2012 | - - |
Pathogenic, criteria provided, single submitter | curation | CFTR-France | Jan 29, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 12, 2023 | This sequence change replaces methionine, which is neutral and non-polar, with lysine, which is basic and polar, at codon 1101 of the CFTR protein (p.Met1101Lys). This variant is present in population databases (rs36210737, gnomAD 0.004%). This missense change has been observed in individual(s) with cystic fibrosis (PMID: 7680525, 9383031, 9439669, 10439967, 17901983, 22981120, 23974870). It is commonly reported in individuals of Hutterite ancestry (PMID: 7680525, 9383031, 9439669, 10439967, 17901983, 22981120, 23974870). ClinVar contains an entry for this variant (Variation ID: 39516). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CFTR protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | Nov 05, 2018 | - - |
Pathogenic, reviewed by expert panel | research | CFTR2 | Mar 17, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 04, 2019 | NM_000492.3(CFTR):c.3302T>A(M1101K) is classified as pathogenic in the context of cystic fibrosis. Sources cited for classification include the following: PMID 7680525, 23974870 and 18456578. Classification of NM_000492.3(CFTR):c.3302T>A(M1101K) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
not provided Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 24, 2017 | The CFTR c.3302T>A, p.Met1101Lys variant (rs36210737) has been reported in multiple individuals diagnosed with cystic fibrosis, and either found homozygously or in-trans with another pathogenic variant (Ooi 2012, Sosnay 2013, Stanke 2008, Stuhrmann 1997, Zielenski 1993, CFTR2 database). Functional characterization of the variant indicates impairment in CFTR protein maturation, resulting in an absence of chloride transport activity (Seibert 1996, Sosnay 2013, Van Goor 2014). The variant is listed as pathogenic in ClinVar (Variation ID: 39516), and observed 4 times in the Genome Aggregation Database general population database (4/245882 alleles). The methionine at position 1101 is moderately conserved, and computational algorithms (Mutation Taster, PolyPhen-2, SIFT) predict that the variant has an impact on CFTR protein structure or function. Based on the above information, the p.Met1101Lys variant is classified as moderately pathogenic. References: CFTR2 databsae: http://cftr2.org/ Ooi C. et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. J Cyst Fibros. 2012; 11(5):355-62. Seibert F et al. Disease-associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity. J Biol Chem. 1996; 271(25):15139-45. Sosnay PR et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013; 45(10):1160-7. Stanke F et al. Diversity of the basic defect of homozygous CFTR mutation genotypes in humans. J Med Genet. 2008; 45(1):47-54. Stuhrmann M et al. Detection of 100 percent of the CFTR mutations in 63 CF families from Tyrol. Clin Genet. 1997; 52(4):240-6. Zielenski J et al. Identification of the M1101K mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and complete detection of cystic fibrosis mutations in the Hutterite population. Am J Hum Genet. 1993; 52(3):609-15. - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Apr 12, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2024 | CFTR: PM3:Very Strong, PP1:Strong, PM2, PM5 - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 06, 2018 | Variant summary: CFTR c.3302T>A (p.Met1101Lys) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 245882 control chromosomes (gnomAD). c.3302T>A has been reported in the literature in multiple individuals affected with Cystic Fibrosis (Chong_2012, Hirtz_2004, Heim_2001, Hogenauer_2001, Larriba_2001, Liechti-Gallati_1999, Stuhrmann_1997, Zielenski_1993). These data indicate that the variant is very likely to be associated with disease. Experimental evidence evaluating an impact on protein function, demonstrated that expression of the variant inhibits the biosynthetic maturation of CFTR and causes its retention in the endoplasmic reticulum (Seibert_1996). Three ClinVar submissions from clinical diagnostic laboratories and reputable databases (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
CFTR-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 17, 2017 | - - |
Cystic fibrosis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Cystic fibrosis;C0238339:Hereditary pancreatitis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation;C2749757:Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 25, 2022 | - - |
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Oct 13, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at